Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EMD 521873 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Dose escalation of EMD 521873 monotheraphy 3 doses per cycle |
| Group 2 | EXPERIMENTAL | Low dose CPA + Dose escalation of EMD 521873 three doses per cycle |
| Group 3 | EXPERIMENTAL | Dose escalation of EMD 521873 monotheraphy 1 dose per cycle |
| Name | Type | Description |
|---|---|---|
| EMD 521873 | BIOLOGICAL | Dose escalation steps: Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg) Disease control and decision of continuation in patient who benefit from the treatment: Every second cycle |
Inclusion Criteria: 1. Signed written informed consent 2. Male or female, aged ≥ 18 years, inpatient for treatment phase of cycle 1 and 2, outpatient treatment possible for subsequent cycles 3. Histologically or cytologically proven metastatic or locally advanced solid tumors (epithelial or mesench...
EMD 521873 is a monoclonal antibody being developed for the treatment of Non-Hodgkin Lymphoma. It is an investigational therapy currently in clinical development for this oncology indication.
EMD 521873 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK.
EMD 521873 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities for commercial use.
EMD 521873 has been studied in one completed Phase 1 clinical trial, identified as NCT01032681. This trial enrolled 66 participants and was conducted in Germany and Switzerland.
The completed Phase 1 trial of EMD 521873 was not randomized and was not double-blinded. The trial was controlled, meaning participants received a control treatment for comparison.
EMD 521873 is a monoclonal antibody, a type of biologic therapy designed to target specific proteins involved in disease. Its exact molecular target has not been disclosed in available clinical trial information.